An Overview of a Study Combining Nivolumab With Ibrutinib in CLL and Richter Transformation

Video

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses a phase II trial combining nivolumab (Opdivo) with ibrutinib (Imbruvica) for chronic lymphocytic leukemia (CLL) and richter transformation (RT) during the American Society of Hematology (ASH) Annual Meeting.<br /> &nbsp;

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses a phase II trial combining nivolumab (Opdivo) with ibrutinib (Imbruvica) for chronic lymphocytic leukemia (CLL) and richter transformation (RT) during the American Society of Hematology (ASH) Annual Meeting.

Recent Videos
Related Content
Early Palliative Care Improves EOL Comfort in Colorectal Cancer

Early Palliative Care Improves EOL Comfort in Colorectal Cancer

Roman Fabbricatore
January 30th 2025
Article

Early palliative care reduces invasive interventions and enhances comfort at EOL for CRC patients, according to real-world study results.

Read More

Understanding the Role of Zanubrutinib for the Treatment of CLL

Understanding the Role of Zanubrutinib for the Treatment of CLL

Rohit Gosain, MD;Rahul Gosain, MD
April 23rd 2024
Podcast

Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

Listen

Oral Paclitaxel Outperforms IV in OS for Advanced Gastric Cancer

Oral Paclitaxel Outperforms IV in OS for Advanced Gastric Cancer

Ryan Scott
January 28th 2025
Article

Oral paclitaxel matched IV in progression-free survival but outperformed it in overall survival for second-line advanced gastric cancer.

Read More

Exciting Activity in Chronic Lymphocytic Leukemia

Exciting Activity in Chronic Lymphocytic Leukemia

Nichole Tucker;Cyrus M. Khan, MD
May 31st 2023
Podcast

In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

Listen

Fruquintinib and TAS-102 Effective in Heavily Pretreated mCRC

Fruquintinib and TAS-102 Effective in Heavily Pretreated mCRC

Jax DiEugenio
January 27th 2025
Article

Fruquintinib plus TAS-102 showed clinical activity in heavily pretreated metastatic colorectal cancer.

Read More

Palliative Care Consultations Enhance QOL, Reduce Costs in End-of-Life Esophageal Cancer Care

Palliative Care Consultations Enhance QOL, Reduce Costs in End-of-Life Esophageal Cancer Care

Tim Cortese
January 27th 2025
Article

Palliative care consultations in esophageal cancer improved QOL and reduced financial burden, according to ASCO GI poster findings.

Read More